A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

Bitter taste receptor has hidden intracellular pocket that enables activation via simultaneous extracellular/intracellular ...

The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...